RxDoctor Payments DataLook up a doctor →

William Smith, MD

Cardiovascular Disease · Ruston, LANPI 1992776231

Payments from drug & device makers

$693,535in general payments, 2019–2025

Across 478 payments — averaging $1450.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$549K
  • Astrazeneca UK Limited$74K
  • Organon$63K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$985
  • AstraZeneca$786
  • Sanofi-aventis U.S. LLC$538
  • plus $5K from 36 others
$1,397in research payments, 2019–2025

Across 1 payment — averaging $1397.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$693,535 in reported general payments places this provider in the 95th percentile of 281 cardiovascular disease providers in Louisiana.

See all cardiovascular disease providers in Louisiana

Medicare billing

Part B allowed, 2024
$281,548
Medicare patients
959
Services billed
4,494

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other cardiovascular disease in Ruston

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →